On-demand Webcast

Share

Program Content

Activities

  • HER2- and TROP-2–Targeted Tx in Breast Cancer
    Optimizing Integration of Precision Therapy Into the Treatment of HER2-Low, HR-Positive, and Triple Negative Breast Cancer: A Focus on HER2 Targeted and TROP-2–Targeted Therapy
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 20, 2023

    Expires: June 19, 2024

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

AstraZeneca

Daiichi Sankyo

Gilead Sciences, Inc.